Gene Therapy Shows Promise for Fatal Childhood Disease

Children with Friedreich's ataxia face a heartbreaking reality: progressive nerve damage that steals their ability to walk, often before their teenage years. Now, researchers in London have created an experimental gene therapy that could stop the disease before it ever starts.

Scientists at Brunel University and University College London have developed a treatment using genetically modified stem cells. The therapy addresses the root cause of Friedreich's ataxia, a missing protein called frataxin that cells need to produce energy.

The approach transforms a patient's own blood stem cells into tiny factories that continuously produce the missing protein. Doctors remove the cells, modify them in a lab using a virus to deliver an engineered frataxin gene, and return them to the body where they settle in bone marrow and start pumping out the vital protein.

In laboratory tests with mice, the results exceeded expectations. Treated animals showed improved coordination and movement compared to untreated ones. Their brain, heart, and muscle tissues had frataxin levels restored to near normal.

The team also successfully modified stem cells taken from actual Friedreich's ataxia patients, proving the technique could work with a patient's own cells. This matters because using someone's own cells dramatically reduces the risk of rejection after transplantation.

Friedreich's ataxia is the most common inherited form of ataxia, affecting balance and movement. Symptoms typically emerge between ages five and ten, worsening over time until many children need wheelchairs in their teens. The disease also damages the heart, often leading to fatal heart failure. Currently, no cure exists and treatments only manage symptoms.

Why This Inspires

Professor Arturo Sala, who led the Brunel team, explains the treatment's revolutionary potential. Because engineered stem cells remain in the body indefinitely, they could provide a continuous protein supply for life instead of requiring repeated injections.

Dr. Giorgia Santilli from UCL Great Ormond Street Institute puts it simply: "If treatment is given early enough, then patients would not develop the disease and would live almost normal lives." That statement represents hope parents of affected children desperately need.

The research remains in early stages, requiring more animal studies before human trials begin. Professor Sala estimates the therapy will need three to five years and additional funding before testing in patients can start.

If successful in humans, this approach could transform treatment for rare genetic diseases. Rather than managing symptoms or delivering temporary fixes, doctors could turn patients' own cells into permanent biological therapies.

Dr. Julie Greenfield, Director of Research at Ataxia UK, called the findings "promising preclinical data" and thanked researchers on behalf of families affected by the condition. Families who've watched their children struggle now have reason to hope for a future where the disease never takes hold.